Adagrasib Active, Safe Among Patients with KRAS G12C-Mutated Pancreatic, GI Tumors
Adagrasib induced promising clinical activity as monotherapy among pretreated patients with unresectable or metastatic pancreatic cancer and other gastrointestinal tumors that harbor a KRAS G12C mutation, according to study results.
The agent also had a manageable safety profile, research presented at ASCO Gastrointestinal Cancers Symposium showed. Read more . . .